# Alto Invest

> Alto Invest is a VC fund in Versailles backing Software and Health Care. See 16 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Versailles, France
- Total investments: 16
- Last investment: Oct 2019
- Lead investor: 25%
- Last updated: Aug 2026
- Website: http://www.altoinvest.fr

Alto Invest is a VC fund in Versailles focused on Software and Health Care. ALTO INVEST was founded by partners Antoine Valdes and Jean-François Paumelle, who have worked together since 1994 for one of Europe's largest financial institutions. Their team has managed several portfolios on behalf of institutional and private clients, and made more than 50 private equity investments in Europe, North America and Asia.

## Contacts

5 contacts available for Alto Invest. Shizune tracks 8 team members at Alto Invest. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/alto-invest?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $1.5M–$4.6M |
| Convertible Note | $2.1M–$8.4M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 4 | 25% |
| Health Care | 3 | 19% |
| Biotechnology | 3 | 19% |
| SaaS | 2 | 13% |
| Marketing | 2 | 13% |

38 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 31% |
| Funding Round | 5 | 31% |
| Convertible Note | 2 | 13% |
| Series C | 1 | 6% |
| Private Equity | 1 | 6% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 11 | 69% |
| Martinique | 1 | 6% |
| United States | 1 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Franck Halley | Associate Director | 1 | https://shizune.co/investors/profile/franck-halley |
| Jean-François Paumelle | Managing Director | 1 | https://shizune.co/investors/profile/jean-franois-paumelle |
| Benoit Thiedey | Head of Investments | 0 | https://shizune.co/investors/profile/benoit-thiedey |
| Emilie Da Silva | Head of Investments | 0 | https://shizune.co/investors/profile/emilie-da-silva |
| Marie Conilh de Beyssac | Back Office Manager - Partner Relations | 0 | https://shizune.co/investors/profile/marie-conilh-de-beyssac |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Karos | Karos transform available car seats into public transport networks, leveraging AI and mobile technologies. | $2.1M | Convertible Note | Oct 06, 2019 |  |
| Crème de la Crème | Crème de la Crème connects companies with the most talented freelancers in Europe. Crème de la Crème was launched by Jean-Charles Varlet, Théo Dorp and Romain Abidonn in April 2015. | $3.2M | Series A | Jun 27, 2018 |  |
| Crème de la Crème | Crème de la Crème connects companies with the most talented freelancers in Europe. Crème de la Crème was launched by Jean-Charles Varlet, Théo Dorp and Romain Abidonn in April 2015. | $3.3M | Series A | Jun 27, 2018 |  |
| Karos | Karos transform available car seats into public transport networks, leveraging AI and mobile technologies. | $4.6M | Series A | Apr 16, 2018 |  |
| Unow | Unow delivers tutored training programs on project management, soft skills and business skills. With a portfolio of 50+ training programs and a network of 100+ field experts, our goal is to improve team collaboration and productivity. Unow is headquartered in Paris, France. | $3.3M |  | Oct 02, 2017 |  |
| Nosopharm | Nosopharm is a young innovative biotechnology company dedicated to anti-infective drug discovery. Nosopharm addresses the unmet medical need of the bacterial multidrug resistance to antibiotics, a very concerning issue for hospital-acquired infections.Nosopharm has set up an innovative anti-infective drug discovery platform based on themedicinal mining of the microbial biodiversity. The company has developed a unique expertise in the screening and the characterization of bioactive secondary metabolites produced by an original microbial bioresource: the bacterial genera Xenorhabdus and Photorhabdus. | $2.6M |  | Mar 28, 2017 |  |
| EasyVista | EasyVista simplifies IT Service Management by making it easy to deliver and easy to use for today’s enterprise. EasyVista’s service management platform was created to help companies automate and personalize service delivery to improve IT efficiency and increase staff productivity. Today, EasyVista helps 1,000+ enterprises around the world radicallyimprove service user experience, dramatically simplify and accelerate service creation, and reduce the total cost of IT service delivery. EasyVista serves companies across a variety of industries, including financial services, healthcare, higher education, technology, public sector, retail, manufacturing and more. Headquartered in New York and Paris, EasyVista is a rapidly growing global company backed by leading venture capitalists. | $8.4M | Convertible Note | Aug 17, 2016 |  |
| Nosopharm | Nosopharm is a young innovative biotechnology company dedicated to anti-infective drug discovery. Nosopharm addresses the unmet medical need of the bacterial multidrug resistance to antibiotics, a very concerning issue for hospital-acquired infections.Nosopharm has set up an innovative anti-infective drug discovery platform based on themedicinal mining of the microbial biodiversity. The company has developed a unique expertise in the screening and the characterization of bioactive secondary metabolites produced by an original microbial bioresource: the bacterial genera Xenorhabdus and Photorhabdus. | $954K |  | Nov 07, 2013 |  |
| DigiSchool | digiSchool offers various learning tools for each educational stage from primary school through to postbaccalaureate, with the majority of their users in the 15-25 year old range. They were one of the first e-learning outfits to anticipate the eventual dominance of mobile in the learning space amongst younger generations, and seamlessly made thetransition to mobile earlier on. | $3.3M | Series A | Jun 28, 2013 |  |
| SpineVision | SpineVision is a spinal technology company focused on the development and marketing of implants and instrumentation for spinal treatment. The company offers spinal systems addressing a wide range of spinal pathologies including degenerative disc disease, deformity, cervical disorders, trauma and tumors. These products have been developed incollaboration with leading neurological and orthopedic surgeons which has resulted in over 20 patents.SpineVision was founded in 1999 and is headquartered in Antony in France, with subsidiaries in Belgium, Italy, the United Kingdom, and the United States. | $10M |  | May 07, 2013 |  |

10 of 16 investments shown.

## Co-investors
- [Auriga Partners](https://shizune.co/investors/profile/auriga-partners) — VC Fund, 3 deals together
- [Aglaé Ventures](https://shizune.co/investors/profile/aglae-ventures) — VC Fund, 2 deals together
- [Aster](https://shizune.co/investors/profile/aster-capital) — VC Fund, 2 deals together
- [BNP Paribas Private Equity](https://shizune.co/investors/profile/bnp-paribas-private-equity) — VC Fund, 2 deals together
- [Financiere Saint James](https://shizune.co/investors/profile/financiere-saint-james) — VC Fund, 2 deals together
- [M Capital Partners](https://shizune.co/investors/profile/m-capital-partners) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Kima Ventures](https://shizune.co/investors/profile/kima-ventures) — VC Fund
- [Motier Ventures](https://shizune.co/investors/profile/motier-ventures) — VC Fund

## Featured in investor lists
- [Mobile VC Funds in France](https://shizune.co/investors/mobile-vc-funds-france)
- [Recruiting VC Funds in Europe](https://shizune.co/investors/recruiting-vc-funds-europe)
- [Recruiting Investors in France](https://shizune.co/investors/recruiting-investors-france)
- [Biotechnology VC Funds in France](https://shizune.co/investors/biotechnology-vc-funds-france)
- [Biotech Investors in France](https://shizune.co/investors/biotech-investors-france)
- [Biotechnology Investors in France](https://shizune.co/investors/biotechnology-investors-france)

## FAQ

### What does Alto Invest invest in?

Alto Invest invests primarily in Software, Health Care and Biotechnology startups, most often at Series A and Funding Round stage. Most of the 16 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Alto Invest's check size?

Alto Invest typically joins rounds of $1.5M–$4.6M at Series A and $2.1M–$8.4M at Convertible Note. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Alto Invest participates in.

### How do I contact Alto Invest?

Public channels for Alto Invest include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Alto Invest?

The team at Alto Invest includes Franck Halley (Associate Director), Jean-François Paumelle (Managing Director) and Benoit Thiedey (Head of Investments), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co